Antimicrobial Resistance in Mycobacterium tuberculosis: The Odd One Out

Trends in Microbiology

Volumn 24, Issue 8, 2016, Pages 637-648

  Eldholm, Vegard ^a   Balloux, François ^b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antibiotics; biofilms; evolution; latency; mutation; transmission; tuberculosis

Indexed keywords

AMINOGLYCOSIDE; CHLORAMPHENICOL; ISONIAZID; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIAL TRANSMISSION; CHEMICAL WARFARE; DRUG PENETRATION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENETIC VARIABILITY; HORIZONTAL GENE TRANSFER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MIXED INFECTION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION RATE; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; BIOFILM; EVOLUTION; GENETIC VARIATION; GENETICS; LATENT TUBERCULOSIS; LIFE CYCLE STAGE; MICROBIOLOGY; MUTATION; PHYSIOLOGY; TRANSMISSION; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; BIOFILMS; BIOLOGICAL EVOLUTION; DRUG RESISTANCE, BACTERIAL; GENE TRANSFER, HORIZONTAL; GENETIC VARIATION; HUMANS; LATENT TUBERCULOSIS; LIFE CYCLE STAGES; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84975275058     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2016.03.007     Document Type: Review

References (91)

1. 1 Achtman, M., Evolution, population structure, and phylogeography of genetically monomorphic bacterial pathogens. Annu. Rev. Microbiol. 62 (2008), 53–70.
2. 2 Cohen, K.A., et al. Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal. PLoS Med., 12, 2015, e1001880.
3. 3 Eldholm, V., et al. Four decades of transmission of a multidrug-resistant Mycobacterium tuberculosis outbreak strain. Nat. Commun., 6, 2015, 7119.
4. 4 Smith, S.E., et al. Comparative genomic and phylogenetic approaches to characterize the role of genetic recombination in mycobacterial evolution. PLoS ONE, 7, 2012, e50070.
5. 5 Reva, O., et al. Role of the horizontal gene exchange in evolution of pathogenic mycobacteria. BMC Evol. Biol., 15(Suppl. 1), 2015, S2.
6. 6 Gray, T.A., et al. Distributive conjugal transfer in mycobacteria generates progeny with meiotic-like genome-wide mosaicism, allowing mapping of a mating identity locus. PLoS Biol., 11, 2013, e1001602.
7. 7 Mortimer, T.D., Pepperell, C.S., Genomic signatures of distributive conjugal transfer among mycobacteria. Genome Biol. Evol. 6 (2014), 2489–2500.
8. 8 Morris, R.P., et al. Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 102 (2005), 12200–12205.
9. 9 Veyrier, F.J., et al. The rise and fall of the Mycobacterium tuberculosis genome. Trends Microbiol. 19 (2011), 156–161.
10. 10 World Health Organisation. Global leprosy: Update on the 2012 situation. Wkly. Epidemiol. Rec. 88 (2013), 365–379.
11. 11 Rowe, M.T., Grant, I.R., Mycobacterium avium ssp. paratuberculosis and its potential survival tactics. Lett. Appl. Microbiol. 42 (2006), 305–311.
12. 12 Stinear, T.P., et al. Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res. 18 (2008), 729–741.
13. 13 Gutierrez, M.C., et al. Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis. PLoS Pathog., 1, 2005, e5.
14. 14 Koeck, J.L., et al. Clinical characteristics of the smooth tubercle bacilli ‘Mycobacterium canettii’ infection suggest the existence of an environmental reservoir. Clin. Microbiol. Infect. 17 (2011), 1013–1019.
15. 15 Supply, P., et al. Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. Nat. Genet. 45 (2013), 172–179.
16. 16 Pepperell, C.S., et al. The role of selection in shaping diversity of natural M. tuberculosis populations. PLoS Pathog., 9, 2013, e1003543.
17. 17 Namouchi, A., et al. After the bottleneck: Genome-wide diversification of the Mycobacterium tuberculosis complex by mutation, recombination, and natural selection. Genome Res. 22 (2012), 721–734.
18. 18 Farhat, M.R., et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat. Genet. 45 (2013), 1183–1189.
19. 19 Luria, S.E., Delbrück, M., Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28 (1943), 491–511.
20. 20 Roetzer, A., et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS Med., 10, 2013, e1001387.
21. 21 Walker, T.M., et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect. Dis. 13 (2013), 137–146.
22. 22 Ford, C.B., et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat. Genet. 45 (2013), 784–790.
23. 23 Krašovec, R., et al. Mutation rate plasticity in rifampicin resistance depends on Escherichia coli cell–cell interactions. Nat. Commun., 5, 2014, 3742.
24. 24 Bos, K.I., et al. Pre-Columbian mycobacterial genomes reveal seals as a source of New World human tuberculosis. Nature 514 (2014), 494–497.
25. 25 Kay, G.L., et al. Eighteenth-century genomes show that mixed infections were common at time of peak tuberculosis in Europe. Nat. Commun., 6, 2015, 6717.
26. 26 Wirth, T., et al. Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog., 4, 2008, e1000160.
27. 27 Comas, I., et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat. Genet. 45 (2013), 1176–1182.
28. 28 Lee, O.Y.C., et al. Lipid biomarkers provide evolutionary signposts for the oldest known cases of tuberculosis. Tuberculosis 95:Suppl. 1 (2015), S127–S132.
29. 29 Baker, O., et al. Human tuberculosis predates domestication in ancient Syria. Tuberculosis 95:Suppl. 1 (2015), S4–S12.
30. 30 Lee, O.Y.C., et al. Mycobacterium tuberculosis complex lipid virulence factors preserved in the 17,000-year-old skeleton of an extinct bison, Bison antiquus. PLoS ONE, 7, 2012, e41923.
31. 31 Hershkovitz, I., et al. Detection and molecular characterization of 9,000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. PLoS ONE, 3, 2008, e3426.
32. 32 Sloot, R., et al. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am. J. Resp. Crit. Care Med. 190 (2014), 1044–1052.
33. 33 Barry, C.E., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7 (2009), 845–855.
34. 34 Tocque, K., et al. Long-term trends in tuberculosis. Am. J. Resp. Crit. Care Med. 158 (1998), 484–488.
35. 35 Gagneux, S., Host–pathogen coevolution in human tuberculosis. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 367 (2012), 850–859.
36. 36 de Jong, B.C., et al. Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J. Infect. Dis. 198 (2008), 1037–1043.
37. 37 Guerrero, M.I., et al. Is drug-resistant Mycobacterium leprae a real cause for concern?: First approach to molecular monitoring of multibacillary Colombian patients with and without previous leprosy treatment. Biomedica 34:Suppl. 1 (2014), 137–147.
38. 38 Lavania, M., et al. Emergence of primary drug resistance to rifampicin in Mycobacterium leprae strains from leprosy patients in India. Clin. Microbiol. Infect. 21 (2015), e85–e86.
39. 39 Matsuoka, M., et al. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines. Leprosy Rev. 78 (2007), 343–352.
40. 40 Ritacco, V., et al. Nosocomial Spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J. Infect. Dis. 176 (1997), 637–642.
41. 41 Small, P.M., et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N. Engl. J. Med. 328 (1993), 1137–1144.
42. 42 Wells, C.D., et al. HIV Infection and multidrug-resistant tuberculosis – the perfect storm. J. Infect. Dis. 196 (2007), S86–S107.
43. 43 Suchindran, S., et al. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS ONE, 4, 2009, e5561.
44. 44 Merker, M., et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat. Genet. 47 (2015), 242–249.
45. 45 Udwadia, Z.F., et al. Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades?. PLoS ONE, 5, 2010, e12023.
46. 46 Bifani, P.J., et al. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol. 10 (2002), 45–52.
47. 47 Werngren, J., Hoffner, S.E., Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J. Clin. Microbiol. 41 (2003), 1520–1524.
48. 48 Hunter, R.L., Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis 91 (2011), 497–509.
49. 49 Hunter, R.L., et al. Multiple roles of cord factor in the pathogenesis of primary, secondary, and cavitary tuberculosis, including a revised description of the pathology of secondary disease. Ann. Clin. Lab. Sci. 36 (2006), 371–386.
50. 50 Hunter, R.L., et al. Pathogenesis of post primary tuberculosis: immunity and hypersensitivity in the development of Cavities. Ann. Clin. Lab. Sci. 44 (2014), 365–387.
51. 51 Osler, W., Tuberculosis. In The Principles and Practice of Medicine. 1892, Appleton, 184–255.
52. 52 Kjellsson, M.C., et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 56 (2012), 446–457.
53. 53 Schecter, G.F., et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis. 50 (2010), 49–55.
54. 54 Moreno-Gamez, S., et al. Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), E2874–E2883.
55. 55 Kritski, A.L., et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 111 (1997), 1162–1167.
56. 56 Kempker, R.R., et al. Acquired drug resistance in Mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis. Emerg. Infect. Dis. 21 (2015), 992–1001.
57. 57 Shin, S.S., et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am. J. Respir. Crit. Care Med. 182 (2010), 426–432.
58. 58 Srivastava, S., et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J. Infect. Dis. 204 (2011), 1951–1959.
59. 59 Ojha, A.K., et al. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol. Microbiol. 69 (2008), 164–174.
60. 60 Sambandan, D., et al. Keto-mycolic acid-dependent pellicle formation confers tolerance to drug-sensitive Mycobacterium tuberculosis. MBio, 4, 2013 e00222-00213.
61. 61 Eldholm, V., et al. Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient. Genome Biol., 15, 2014, 490.
62. 62 Merker, M., et al. Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients. PLoS ONE, 8, 2013, e82551.
63. 63 O'Neill, M.B., et al. Diversity of Mycobacterium tuberculosis across evolutionary scales. PLoS Pathog., 11, 2015, e1005257.
64. 64 Perez-Lago, L., et al. Whole genome sequencing analysis of intrapatient microevolution in Mycobacterium tuberculosis: potential impact on the inference of tuberculosis transmission. J. Infect. Dis. 209 (2014), 98–108.
65. 65 Sun, G., et al. Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J. Infect. Dis. 206 (2012), 1724–1733.
66. 66 Pillay, M., Sturm, A.W., Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45 (2007), 1409–1414.
67. 67 Brandis, G., Hughes, D., Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. J. Antimicrob. Chemother. 68 (2013), 2493–2497.
68. 68 Comas, I., et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 44 (2012), 106–110.
69. 69 Gagneux, S., et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog., 2, 2006, e61.
70. 70 Pym, A.S., et al. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect. Immun. 70 (2002), 4955–4960.
71. 71 Nessar, R., et al. Mycobacterium abscessus: a new antibiotic nightmare. J. Antimicrob. Chemother. 67 (2012), 810–818.
72. 72 Bryant, J.M., et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 381 (2013), 1551–1560.
73. 73 Nash, K.A., et al. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob. Agents Chemother. 53 (2009), 1367–1376.
74. 74 Turenne, C.Y., et al. Mycobacterium avium subsp. paratuberculosis and M. avium subsp. avium are independently evolved pathogenic clones of a much broader group of M. avium organisms. J. Bacteriol. 190 (2008), 2479–2487.
75. 75 Doig, K.D., et al. On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics, 13, 2012, 258.
76. 76 Guenin-Macé, L., et al. Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 12833–12838.
77. 77 Fyfe, J.A.M., et al. A major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Neglect. Trop. Dis., 4, 2010, e791.
78. 78 MRC Cardiothoracic Epidemiology Group Unit. National survey of tuberculosis notifications in England and Wales in 1983: Characteristics of disease. Tubercle 68 (1987), 19–32.
79. 79 Marks, J., Drug resistance in untreated pulmonary tuberculosis in England and Wales during 1960. A survey by the Public Health Laboratory Service. Tubercle 42 (1961), 308–313.
80. 80 Kruijshaar, M.E., et al. Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. BMJ 336 (2008), 1231–1234.
81. 81 Rose, A.M.C., et al. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax 56 (2001), 173–179.
82. 82 Reacher, M.H., et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 320 (2000), 213–216.
83. 83 Johnson, A.P., James, D., Continuing increase in invasive methicillin-resistant infection. Lancet, 350, 1997, 1710.
84. 84 Speller, D.C., et al. Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989–95. Lancet 350 (1997), 323–325.
85. 85 D'Souza, D.T., et al. High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health, 9, 2009, 211.
86. 86 Dalal, A., et al. Resistance patterns among multidrug-resistant tuberculosis patients in Greater Metropolitan Mumbai: trends over time. PLoS ONE, 10, 2015, e0116798.
87. 87 Isaakidis, P., et al. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in Metropolitan Mumbai, India. PLoS ONE, 9, 2014, e110461.
88. 88 Massyn, N., et al. District Health Barometer 2013/2014. Health System Trust, 2014.
89. 89 Coovadia, Y.M., et al. Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region. PLoS ONE, 8, 2013, e77712.
90. 90 Skrahina, A., et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur. Resp. J. 39 (2012), 1425–1431.
91. 91 Skrahina, A., et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull. World Health Organ. 91 (2013), 36–45.